---
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/ISO11179Concepts#label
  :object: LY246708
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/ISO11179Types#changeDescription
  :object: ''
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/ISO11179Types#creationDate
  :object: '2016-01-01T00:00:00+00:00'
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/ISO11179Types#explanatoryComment
  :object: ''
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/ISO11179Types#hasIdentifier
  :object: http://www.transceleratebiopharmainc.com/LY246708/V1#PR_SI
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/ISO11179Types#hasState
  :object: http://www.transceleratebiopharmainc.com/LY246708/V1#PR_RS
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/ISO11179Types#lastChangeDate
  :object: '2020-11-16T15:05:45+01:00'
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/ISO11179Types#origin
  :object: ''
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#acronym
  :object: H2Q-MC-LZZT
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#forIndication
  :object: http://www.transceleratebiopharmainc.com/IND_ALZ/V1#IND
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#inTa
  :object: http://www.transceleratebiopharmainc.com/TA_NSD/V1#TA
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#interventionModel
  :object: http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC1
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#masking
  :object: http://www.transceleratebiopharmainc.com/FLU001/V1#PR_TUC2
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#shortTitle
  :object: LY246708
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#specifiesArm
  :object: http://www.assero.co.uk/ARM#3fc48141-7933-4eb2-bcc2-7a9048f5da4b
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#specifiesArm
  :object: http://www.assero.co.uk/ARM#700c7fd7-03a4-4506-bd2f-0b8323bef630
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#specifiesArm
  :object: http://www.assero.co.uk/ARM#9742e98d-2a56-4e68-b43c-f49a975d30ee
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#specifiesEpoch
  :object: http://www.assero.co.uk/EP#090d893f-33fe-41de-abe2-2d2d793a3af2
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#specifiesEpoch
  :object: http://www.assero.co.uk/EP#740a029c-e7f7-4fed-a53c-9e0c4763ebeb
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#specifiesObjective
  :object: http://www.assero.co.uk/PROBJ#81281c98-cea9-4208-bd60-407a8521f895
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#specifiesObjective
  :object: http://www.assero.co.uk/PROBJ#ac5049f7-5496-47d4-9bd8-1f7d11c7c536
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#specifiesObjective
  :object: http://www.assero.co.uk/PROBJ#b7af8dce-8c77-41a7-9542-294f00001d1e
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#specifiesObjective
  :object: http://www.assero.co.uk/PROBJ#c2136109-64a6-4cec-8f87-e9a8294f7904
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#studyPhase
  :object: http://www.transceleratebiopharmainc.com/LY246708/V1#PR_TUC3
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#studyType
  :object: http://www.transceleratebiopharmainc.com/LY246708/V1#PR_TUC4
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.assero.co.uk/Protocol#title
  :object: Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS)
    in Patients with Mild to Moderate Alzheimerâ€™s Disease.
- :subject: http://www.transceleratebiopharmainc.com/LY246708/V1#PR
  :predicate: http://www.w3.org/1999/02/22-rdf-syntax-ns#type
  :object: http://www.assero.co.uk/Protocol#Protocol
